MI-2-2

Research use only, not for human use.

MI-2-2 is a potent inhibitor of the menin-MLL interaction that binds to menin with low nanomolar affinity (Kd=22 nM).

MI-2-2 is a potent inhibitor of the menin-MLL interaction that binds to menin with low nanomolar affinity (Kd=22 nM); inhibits the interaction of menin with MLL-AF9 in HEK293 cells in a dose-dependent manner with 4-fold potentcy improvement over MI-2; suppresses growth of MLL-AF9–transformed BMCs; causes MV4:11 cells growth inhibition of with GI50 of 3 uM.

MI-2-2 is capable of inhibiting both the interaction of menin with MBM1 (IC50= 46 nM) and with the bivalent fragment of MLL that comprises both MBM1 and MBM2 (IC50=520 nM). MI-2-2 exhibits very pronounced activities at low micromolar concentrations in BMCs transformed with MLL-AF9 and in MV4;11, a human leukemia cell line harboring the MLL-AF4 translocation.

——

MI-2-2 | MI22 | MI 2 2

Chromatin/Epigenetic

HMTase

HMTase

——

——

1454920-20-7

415.497

C17H20F3N5S2

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (240.67 mM)

FC(F)(F)CC1=CC2=C(N3CCN(C4=NCC(C)(C)S4)CC3)N=CN=C2S1

4-(4-(5,5-Dimethyl-4,5-dihydrothiazol-2-yl)piperazin-1-yl)-6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidine

(-20℃)

With Ice Pack

≥ 2 years